Luminex Corp.

Company: Luminex Corp., Austin, TX
Company Description: Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the diagnostic and life science industries. The company’s open-architecture xMAP® and xTAG® Technologies enable large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.
Nomination Category: Company / Organization Categories
Nomination Sub Category: Most Innovative Company of the Year - Up to 2,500 Employees

Nomination Title: Luminex Corporation

Tell the story about what this nominated company achieved since January 1 2010 (up to 500 words). Focus on specific accomplishments, and relate these accomplishments to past performance or industry norms. Be sure to mention obstacles overcome, innovations or discoveries made, and outcomes:

Since our founding in 1995, Luminex has pioneered the science of simultaneously
detecting multiple substances in a single biological sample, commonly known as
multiplexing. From basic research to new laboratory tests and medicines, from
agricultural science to bioterrorism initiatives, Luminex Corporation develops
solutions that transform markets and improve lives by utilizing world-class
innovation to deliver efficiency and productivity for our customers.

In 2010, we introduced our newest system, MAGPIX®, which broadens our system
portfolio and opens new market segments. Based on Luminex’s xMAP® Technology,
the MAGPIX instrument is compact, robust and easy-to-use, making it attractive
to laboratories and institutions with limited bench space and resources. The
instrument provides fast, accurate and easily reproducible results that can
advance research across many disease states by bringing a broad array of
multiplexing applications to scientists.

The MAGPIX system uses an innovative detection mechanism that employs the use of
advanced light-emitting diode (LED) technology to capture test results. MAGPIX
saves vital time in the laboratory, produces faster results and requires less
sample input than existing legacy technologies. Like other Luminex instruments,
MAGPIX is versatile and flexible and can be used to analyze both nucleic acids
and proteins. Luminex is pleased that our first commercial instrument was
delivered to a scientific team at the Papua New Guinea Institute of Medical
Research, where it is being used to advance critical malaria research.

In addition to our instrumentation initiatives, Luminex and our partners
introduced new assays that broaden the scope and power of xMAP Technology. In
August, we launched the broadest available FDA 510(k)-cleared assay to detect
genetic mutations associated with cystic fibrosis (CF), which simultaneously
determines whether a single blood sample has up to 60 of the more common
disease-causing mutations, providing test results in just a few hours.

With our new partner High Throughput Genomics, Inc. (HTG), we co-developed and
launched the qBead™ Gene Expression Assay. qBead is designed for researchers
studying how genes are activated and suppressed in disease versus normal states.
From this, they ascertain a better understanding of how such diseases develop,
and can identify new targets for drug discovery.

Luminex also entered the dynamic field of personalized medicine, which seeks to
provide more effective health care through individualized treatments that are
tailored to a patient’s unique genetic profile. Launched in November, the
in-vitro diagnostic assay, xTAG® CYP2D6 kit measures an enzyme that is involved
in the metabolism of approximately one-fourth of all prescription drugs, from
beta blockers to opioids. Our new test, which received FDA 510(k) clearance from
the U.S. Food and Drug Administration, can help physicians prescribe medications
that will more effectively benefit patients through the knowledge of their 2D6
status.

Finally, our organization comprises a group of talented people who are committed
to making a difference with our customers, partners and, most of all, patients.
By maintaining focus on innovation and addressing previously unmet clinical
research and customer needs, we continue to thrive as an organization, lead in
the market, grow business and innovate solutions to improve human health.

List hyperlinks to any online news stories, press releases, or other documents that support the claims made in the section above. IMPORTANT: Begin each link with http://, and enclose each link in square brackets; for example, [http://www.youraddress.com]:

Provide a brief (up to 100 words) biography about the leader of this nominated company:

Luminex president and CEO since May 2004, Patrick J. Balthrop, has over thirty
years of experience in health care and the medical device industry, including a
diverse track record of achievements as an innovator, product developer, and
accomplished business executive. He previously served as president of Fisher
Healthcare, a Fisher Scientific International company, from 2002 to May 2004.
Since joining Luminex, Mr. Balthrop has developed and executed a strategic
growth plan based on innovation in science and technology, successfully
transforming the company with revenues at Luminex having grown at a compounded
annual growth rate in excess of 20 percent.

Enter Now

Enter Now

Luminex Corp.

Enter Now

Search form

Luminex Corp.